[Prospective monocentric study of the toxicity and the efficacy of concurrent trastuzumab and radiotherapy].
Identifieur interne : 001C52 ( PubMed/Corpus ); précédent : 001C51; suivant : 001C53[Prospective monocentric study of the toxicity and the efficacy of concurrent trastuzumab and radiotherapy].
Auteurs : J. Jacob ; L. Belin ; A. Gobillion ; C. Daveau-Bergerault ; R. Dendale ; P. Beuzeboc ; F. Campana ; M-A Bollet ; A. Fourquet ; Y M KirovaSource :
- Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique [ 1769-6658 ] ; 2013.
English descriptors
- KwdEn :
- Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized (administration & dosage), Antibodies, Monoclonal, Humanized (adverse effects), Antineoplastic Agents (administration & dosage), Antineoplastic Agents (adverse effects), Breast Neoplasms (mortality), Breast Neoplasms (therapy), Carcinoma, Ductal, Breast (mortality), Carcinoma, Ductal, Breast (therapy), Chemoradiotherapy (adverse effects), Esophagitis (etiology), Female, Fibrosis (etiology), Humans, Lymphedema (etiology), Mastectomy, Mastectomy, Segmental, Middle Aged, Pain (etiology), Prospective Studies, Radiodermatitis (etiology), Skin (pathology), Stroke Volume (drug effects), Stroke Volume (radiation effects), Telangiectasis (etiology), Trastuzumab.
- MESH :
- chemical , administration & dosage : Antibodies, Monoclonal, Humanized, Antineoplastic Agents.
- chemical , adverse effects : Antibodies, Monoclonal, Humanized, Antineoplastic Agents.
- adverse effects : Chemoradiotherapy.
- drug effects : Stroke Volume.
- etiology : Esophagitis, Fibrosis, Lymphedema, Pain, Radiodermatitis, Telangiectasis.
- mortality : Breast Neoplasms, Carcinoma, Ductal, Breast.
- pathology : Skin.
- radiation effects : Stroke Volume.
- therapy : Breast Neoplasms, Carcinoma, Ductal, Breast.
- Adult, Aged, Aged, 80 and over, Female, Humans, Mastectomy, Mastectomy, Segmental, Middle Aged, Prospective Studies, Trastuzumab.
Abstract
Prospective monocentric study of the toxicities related to concurrent administration of trastuzumab to breast radiotherapy.
DOI: 10.1016/j.canrad.2012.12.006
PubMed: 23499212
Links to Exploration step
pubmed:23499212Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Prospective monocentric study of the toxicity and the efficacy of concurrent trastuzumab and radiotherapy].</title><author><name sortKey="Jacob, J" sort="Jacob, J" uniqKey="Jacob J" first="J" last="Jacob">J. Jacob</name><affiliation><nlm:affiliation>Département de radiothérapie, institut Curie, 26, rue d'Ulm, 75005 Paris, France. julian.jacob28@gmail.com</nlm:affiliation></affiliation></author><author><name sortKey="Belin, L" sort="Belin, L" uniqKey="Belin L" first="L" last="Belin">L. Belin</name></author><author><name sortKey="Gobillion, A" sort="Gobillion, A" uniqKey="Gobillion A" first="A" last="Gobillion">A. Gobillion</name></author><author><name sortKey="Daveau Bergerault, C" sort="Daveau Bergerault, C" uniqKey="Daveau Bergerault C" first="C" last="Daveau-Bergerault">C. Daveau-Bergerault</name></author><author><name sortKey="Dendale, R" sort="Dendale, R" uniqKey="Dendale R" first="R" last="Dendale">R. Dendale</name></author><author><name sortKey="Beuzeboc, P" sort="Beuzeboc, P" uniqKey="Beuzeboc P" first="P" last="Beuzeboc">P. Beuzeboc</name></author><author><name sortKey="Campana, F" sort="Campana, F" uniqKey="Campana F" first="F" last="Campana">F. Campana</name></author><author><name sortKey="Bollet, M A" sort="Bollet, M A" uniqKey="Bollet M" first="M-A" last="Bollet">M-A Bollet</name></author><author><name sortKey="Fourquet, A" sort="Fourquet, A" uniqKey="Fourquet A" first="A" last="Fourquet">A. Fourquet</name></author><author><name sortKey="Kirova, Y M" sort="Kirova, Y M" uniqKey="Kirova Y" first="Y M" last="Kirova">Y M Kirova</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="RBID">pubmed:23499212</idno><idno type="pmid">23499212</idno><idno type="doi">10.1016/j.canrad.2012.12.006</idno><idno type="wicri:Area/PubMed/Corpus">001C52</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001C52</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[Prospective monocentric study of the toxicity and the efficacy of concurrent trastuzumab and radiotherapy].</title><author><name sortKey="Jacob, J" sort="Jacob, J" uniqKey="Jacob J" first="J" last="Jacob">J. Jacob</name><affiliation><nlm:affiliation>Département de radiothérapie, institut Curie, 26, rue d'Ulm, 75005 Paris, France. julian.jacob28@gmail.com</nlm:affiliation></affiliation></author><author><name sortKey="Belin, L" sort="Belin, L" uniqKey="Belin L" first="L" last="Belin">L. Belin</name></author><author><name sortKey="Gobillion, A" sort="Gobillion, A" uniqKey="Gobillion A" first="A" last="Gobillion">A. Gobillion</name></author><author><name sortKey="Daveau Bergerault, C" sort="Daveau Bergerault, C" uniqKey="Daveau Bergerault C" first="C" last="Daveau-Bergerault">C. Daveau-Bergerault</name></author><author><name sortKey="Dendale, R" sort="Dendale, R" uniqKey="Dendale R" first="R" last="Dendale">R. Dendale</name></author><author><name sortKey="Beuzeboc, P" sort="Beuzeboc, P" uniqKey="Beuzeboc P" first="P" last="Beuzeboc">P. Beuzeboc</name></author><author><name sortKey="Campana, F" sort="Campana, F" uniqKey="Campana F" first="F" last="Campana">F. Campana</name></author><author><name sortKey="Bollet, M A" sort="Bollet, M A" uniqKey="Bollet M" first="M-A" last="Bollet">M-A Bollet</name></author><author><name sortKey="Fourquet, A" sort="Fourquet, A" uniqKey="Fourquet A" first="A" last="Fourquet">A. Fourquet</name></author><author><name sortKey="Kirova, Y M" sort="Kirova, Y M" uniqKey="Kirova Y" first="Y M" last="Kirova">Y M Kirova</name></author></analytic><series><title level="j">Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique</title><idno type="eISSN">1769-6658</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Antibodies, Monoclonal, Humanized (administration & dosage)</term><term>Antibodies, Monoclonal, Humanized (adverse effects)</term><term>Antineoplastic Agents (administration & dosage)</term><term>Antineoplastic Agents (adverse effects)</term><term>Breast Neoplasms (mortality)</term><term>Breast Neoplasms (therapy)</term><term>Carcinoma, Ductal, Breast (mortality)</term><term>Carcinoma, Ductal, Breast (therapy)</term><term>Chemoradiotherapy (adverse effects)</term><term>Esophagitis (etiology)</term><term>Female</term><term>Fibrosis (etiology)</term><term>Humans</term><term>Lymphedema (etiology)</term><term>Mastectomy</term><term>Mastectomy, Segmental</term><term>Middle Aged</term><term>Pain (etiology)</term><term>Prospective Studies</term><term>Radiodermatitis (etiology)</term><term>Skin (pathology)</term><term>Stroke Volume (drug effects)</term><term>Stroke Volume (radiation effects)</term><term>Telangiectasis (etiology)</term><term>Trastuzumab</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antibodies, Monoclonal, Humanized</term><term>Antineoplastic Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antibodies, Monoclonal, Humanized</term><term>Antineoplastic Agents</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Chemoradiotherapy</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Stroke Volume</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Esophagitis</term><term>Fibrosis</term><term>Lymphedema</term><term>Pain</term><term>Radiodermatitis</term><term>Telangiectasis</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Breast Neoplasms</term><term>Carcinoma, Ductal, Breast</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Skin</term></keywords><keywords scheme="MESH" qualifier="radiation effects" xml:lang="en"><term>Stroke Volume</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Breast Neoplasms</term><term>Carcinoma, Ductal, Breast</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Female</term><term>Humans</term><term>Mastectomy</term><term>Mastectomy, Segmental</term><term>Middle Aged</term><term>Prospective Studies</term><term>Trastuzumab</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Prospective monocentric study of the toxicities related to concurrent administration of trastuzumab to breast radiotherapy.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23499212</PMID><DateCreated><Year>2013</Year><Month>06</Month><Day>14</Day></DateCreated><DateCompleted><Year>2013</Year><Month>08</Month><Day>23</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1769-6658</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>3</Issue><PubDate><Year>2013</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique</Title><ISOAbbreviation>Cancer Radiother</ISOAbbreviation></Journal><ArticleTitle>[Prospective monocentric study of the toxicity and the efficacy of concurrent trastuzumab and radiotherapy].</ArticleTitle><Pagination><MedlinePgn>183-90</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.canrad.2012.12.006</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1278-3218(13)00006-1</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Prospective monocentric study of the toxicities related to concurrent administration of trastuzumab to breast radiotherapy.</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">One hundred and seventy-three patients were treated between June 2003 and March 2009 by concurrent trastuzumab with normofractionated radiotherapy. Trastuzumab was delivered every 3 weeks (8mg/kg in the first infusion then 6mg/kg) during a median time of 12 months (2-62). Left ventricular ejection fraction was assessed by echocardiography or cardiac scintigraphy at baseline, before and after radiotherapy, every 3 months for 1 year and annually. A left ventricular ejection fraction strictly lower than 55% was considered as altered. All toxicities were evaluated using Common Terminology Criteria for Adverse Effects version 3.0.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Median follow-up was 52 months (17-88). Median age was 52 years (25-83). One hundred and thirty-four patients (77.5%) received radiotherapy to the internal mammary chain. Acute grade 1, 2 and 3 epithelitis was described in 132 (76.3%), 32 (18.5%) and six patients (3.4%), respectively. At 23 months, grade 1 and 2 fibrosis was observed in 31 and eight patients, respectively (18.8 and 4.6%). Left ventricular ejection fraction remained normal for 159 patients (91.9%) before radiotherapy. Among them, 18 (11.3%) experienced a left ventricular ejection fraction alteration, eight (5.0%) at the completion of radiotherapy. Congestive heart failure occurred in one patient (0.6%).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Toxicities related to the association of trastuzumab to breast radiotherapy were mild. Further follow-up is warranted.</AbstractText><CopyrightInformation>Copyright © 2013 Société française de radiothérapie oncologique (SFRO). Published by Elsevier SAS. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jacob</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Département de radiothérapie, institut Curie, 26, rue d'Ulm, 75005 Paris, France. julian.jacob28@gmail.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Belin</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Gobillion</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Daveau-Bergerault</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Dendale</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Beuzeboc</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Campana</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Bollet</LastName><ForeName>M-A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Fourquet</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Kirova</LastName><ForeName>Y M</ForeName><Initials>YM</Initials></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Étude prospective monocentrique de la toxicité et de l'efficacité du trastuzumab concomitant à la radiothérapie.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2013</Year><Month>03</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Cancer Radiother</MedlineTA><NlmUniqueID>9711272</NlmUniqueID><ISSNLinking>1278-3218</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>P188ANX8CK</RegistryNumber><NameOfSubstance UI="D000068878">Trastuzumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018270" MajorTopicYN="N">Carcinoma, Ductal, Breast</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059248" MajorTopicYN="N">Chemoradiotherapy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004941" MajorTopicYN="N">Esophagitis</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005355" MajorTopicYN="N">Fibrosis</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008209" MajorTopicYN="N">Lymphedema</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008408" MajorTopicYN="N">Mastectomy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015412" MajorTopicYN="N">Mastectomy, Segmental</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010146" MajorTopicYN="N">Pain</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011855" MajorTopicYN="N">Radiodermatitis</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012867" MajorTopicYN="N">Skin</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013318" MajorTopicYN="N">Stroke Volume</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013684" MajorTopicYN="N">Telangiectasis</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068878" MajorTopicYN="N">Trastuzumab</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>05</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2012</Year><Month>12</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>12</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>3</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>3</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>8</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23499212</ArticleId><ArticleId IdType="pii">S1278-3218(13)00006-1</ArticleId><ArticleId IdType="doi">10.1016/j.canrad.2012.12.006</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001C52 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001C52 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:23499212
|texte= [Prospective monocentric study of the toxicity and the efficacy of concurrent trastuzumab and radiotherapy].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:23499212" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |